Olema Pharmaceuticals reported a net loss of $162.5 million for 2025, a widening from the $129.5 million loss in 2024. The fourth‑quarter loss was $46.1 million, up from $33.6 million in Q4 2024, and the company posted a GAAP earnings per share of –$0.50 for the quarter, beating analyst consensus of –$0.51 by $0.01.
Cash, cash equivalents and marketable securities stood at $505.4 million as of December 31 2025. At the current burn rate, the balance supports roughly 2½ years of operations, extending into mid‑2028. The company’s operating cash flow for 2025 was $162.5 million, which, when combined with $12.2 million of interest income, yields a net cash outflow of $150.3 million.
Research and development expenses rose to $157.7 million, a 27 % increase from $124.5 million in 2024, driven by intensified clinical activity for palazestrant and the early‑stage OP‑3136 program. General and administrative costs increased to $21.0 million, while interest income of $12.2 million helped offset some of the operating losses.
In a statement, President and CEO Sean P. Bohen highlighted the company’s progress: “2025 was a year of strong execution across the business as we advanced palazestrant as a differentiated endocrine therapy across multiple regimens, highlighted by continued enrollment and strong investigator interest in our OPERA‑01 and OPERA‑02 trials.” He added that a public offering in November raised $218.5 million, strengthening the balance sheet for upcoming milestones.
The company’s pipeline remains the focus of investor attention. Top‑line data from the OPERA‑01 trial are expected in the fall of 2026, and initial data from the OP‑3136 study are anticipated in Q2 2026. Analyst coverage has reiterated a “Buy” stance, with Stifel maintaining a $48.00 price target and H.C. Wainwright adjusting its target to $38 following Roche’s persevERA results, underscoring the competitive context for palazestrant.
Overall, Olema’s financials reflect heavy investment in late‑stage development, a solid cash position, and a clear path to potential regulatory milestones. The company’s ability to sustain its burn rate while advancing its lead candidate positions it for a pivotal data readout in 2026, after which commercial launch preparations will intensify.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.